We serve Chemical Name:(3E)-4-(3,4-Dimethoxyphenyl)-3-butene-1,2-diol CAS:164661-12-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(3E)-4-(3,4-Dimethoxyphenyl)-3-butene-1,2-diol
CAS.NO:164661-12-5
Synonyms:(3E)-4-(3,4-Dimethoxyphenyl)-3-butene-1,2-diol;3-Butene-1,2-diol, 4-(3,4-dimethoxyphenyl)-, (3E)-
Molecular Formula:C12H16O4
Molecular Weight:224.253
HS Code:2909499000
Physical and Chemical Properties:
Melting point:N/A
Boiling point:422.3±45.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.578
PSA:58.92000
Exact Mass:224.104858
LogP:0.70
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (3E)-4-(3,4-Dimethoxyphenyl)-3-butene-1,2-diol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Butene-1,2-diol, 4-(3,4-dimethoxyphenyl)-, (3E)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Butene-1,2-diol, 4-(3,4-dimethoxyphenyl)-, (3E)- Use and application,(3E)-4-(3,4-Dimethoxyphenyl)-3-butene-1,2-diol technical grade,usp/ep/jp grade.
Related News: Elliott made its intention for a C-suite overhaul clear in an open letter early July. The activist investor called on GSK to appoint a new board directors with biopharma and consumer health expertise to select the leaders for the two companies. sodium 5-hydroxy-4-oxo-2-phenyl-4H-chromene-6,7-diyl bis(sulfate) manufacturers For skin rash, the difference in response rates for anifrolumab versus placebo at week 52 were 13.5% SLE Disease Activity Index (SLEDAI), 15.5% British Isles Lupus Assessment Group index (BILAG) and 15.6% modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI). For arthritis, differences in response rates were 8.2% SLEDAI, 11.8% BILAG and 12.6% joint response. (Z)-19-Oxo-octacos-10-enedioic acid diethyl ester suppliers CanSinoBIO’s inhaled COVID-19 vaccine candidate was found to trigger immune responses with no serious side effects reported, according to an early-stage clinical study. 2-[2-[1-(4-methoxyphenoxy)ethoxy]ethoxy]ethanol vendor & factory.
